
News|Articles|July 21, 2026
Do the Metals in Tampons Pose Any Health Risks?
Author(s)Gillian McGovern, Editor
Fact checked by: Danielle Valletti, Assistant Editor, Ron Panarotti
A new toxicological risk assessment builds on 2024 findings that raised consumer concern, offering pharmacists reassuring data to share with patients.
Advertisement
Advertisement
A new FDA-led toxicological risk assessment has concluded that trace metals detected in tampons do not pose a meaningful health risk to users, addressing concerns first raised by a widely publicized 2024 study.1,2 The investigation, which was published in Toxicological Sciences, examined 11 tampon products legally marketed in the US and determined that, although metals are present in tampon materials, the amount likely to be released and absorbed during typical use falls well within established safety thresholds.1
Related to this article

REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.

Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.

Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.

Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.

In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.

The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Advertisement
Advertisement


